Table 2.
Pharmacokinetic parameters of arctigenin after intravenous (i.v) and hypodermic injection (i.h) AG administrations in beagle dogs (n = 6 per treatment group, results were presented as Mean ± SD).
| Parameters | Units | i.h (dose) |
i.v (dose) |
||
|---|---|---|---|---|---|
| 0.134 μmol/kg | 0.403 μmol/kg | 1.209 μmol/kg | 0.403 μmol/kg | ||
| C5 min | μmol/L | / | / | / | 0.462 ± 0.11 |
| Cmax | μmol/L | 0.032 ± 0.005 | 0.113 ± 0.03 | 0.252 ± 0.04 | / |
| Tmax | Min | 60 | 70.2 ± 15.48 | 75 ± 16.44 | / |
| AUC0-t | Min μmol/L | 4.32 ± 0.54 | 16.61 ± 5.27 | 35.31 ± 4.13 | 15.45 ± 2.02 |
| AUC0-∞ | Min μmol/L | 4.76 ± 0.75 | 16.93 ± 5.42 | 35.63 ± 4.21 | 15.64 ± 2.08 |
| MRT0-∞ | Min | 123.6 ± 14.52 | 120 ± 20.52 | 144.6 ± 23.88 | 53.04 ± 3.55 |
| MRT0-t | Min | 158.4 ± 54.66 | 127.2 ± 26.46 | 153 ± 25.80 | 59.64 ± 5.02 |
| Vd | L/kg | 3.85 ± 0.88 | 2.74 ± 0.72 | 5.87 ± 1.88 | 3.54 ± 0.56 |
| CL | L/min/kg | 0.029 ± 0.05 | 0.026 ± 0.007 | 0.034 ± 0.004 | 0.026 ± 0.004 |
| t1/2 | Min | 94.8 ± 31.74 | 74.4 ± 12.18 | 117 ± 25.44 | 96 ± 24.84 |
| F | 108% | ||||